

Contents

Summary	vii
Zusammenfassung	xi
Abbreviations	xv
1 Introduction to Interstitial Lung Disease in Systemic Sclerosis: Pathogenesis, Challenges and Prospects	1
1.1 Systemic Sclerosis	2
1.2 Interstitial Lung Disease in Systemic Sclerosis (SSc-ILD)	3
1.2.1 Classification of ILDs	3
1.2.2 Pathogenesis of SSc-ILD	5
1.2.3 Cellular Key Players	6
1.3 Challenges and Prospects in the Management of SSc-ILD	10
1.3.1 The Role of Imaging in SSc-ILD: Existing and Emerging Concepts	11
1.3.2 Potential Novel Candidates for Targeted Imaging of ILD	12
1.4 Aim of the Thesis	14
2 Characterization of the Mouse Model of Bleomycin-Induced Lung Fibrosis	17
2.1 Introduction	18
2.2 Results	20
2.2.1 Dose-Response Effects of Bleomycin	20
2.2.2 Time Course of Lung Remodeling	23
2.2.3 Batch Variability of Bleomycin	26
2.3 Discussion	28
2.4 Conclusion	29
2.5 Materials and Methods	30
2.5.1 Animal Experiments	30
2.5.2 Histology	31

2.5.3 Immunohistochemistry	31
2.5.4 Microscopy and Image Analyses	31
2.5.5 Hydroxyproline Assay	32
2.5.6 RNA Extraction and Quantitative Reverse Transcription PCR	32
2.5.7 Statistical Analysis	33
3 Evaluation of [^{99m}Tc]Tc-rhAnnexin V-128-SPECT/CT as a Diagnostic Tool for Early Stages of Interstitial Lung Disease Associated with Systemic Sclerosis	35
3.1 Introduction	36
3.2 Results	37
3.2.1 Apoptosis is an Early Phenomenon in the Development of Lung Fibrosis in Different Murine ILD Models	37
3.2.2 Evaluation of the Potential of [^{99m} Tc]Tc-rhAnnexin V-128 to Visualize Apoptosis in Different Animal Models of ILD	43
3.3 Discussion	45
3.4 Conclusion	47
3.5 Materials and Methods	47
3.5.1 Animal Experiments	47
3.5.2 Histological Analysis	48
3.5.3 TUNEL Assay	48
3.5.4 Immunohistochemical Assessment	49
3.5.5 Immunohistochemical Double Stainings	49
3.5.6 Biodistribution of [^{99m} Tc]Tc-rhAnnexin V-128	50
3.5.7 <i>Ex Vivo</i> Autoradiography	50
3.5.8 <i>In Vivo</i> Imaging using Small Animal SPECT/CT	51
3.5.9 Statistical Analysis	51
4 In-Vivo-Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs	53
4.1 Introduction	54
4.2 Results	56
4.2.1 Characterization of the Mouse Model of Bleomycin-Induced Lung Injury	56
4.2.2 Preparation of Radiolabeled DOTA-PPB-01 and DOTA-PPB-03	57
4.2.3 Biodistribution of [¹⁷⁷ Lu]Lu-DOTA-PPB-01 and [¹⁷⁷ Lu]Lu-DOTA-PPB-03	57
4.2.4 Validation of Binding of [¹⁷⁷ Lu]Lu-DOTA-PPB-01 and [¹⁷⁷ Lu]Lu-DOTA-PPB-03 to Plasma Proteins	60
4.2.5 <i>Ex Vivo</i> SPECT/CT Images of the Lungs	62

4.2.6 Whole-Body SPECT/CT and PET/CT Imaging	63
4.3 Discussion	65
4.4 Conclusion	68
4.5 Materials and Methods	68
4.5.1 <i>In Vivo</i> Experiments	68
4.5.2 Intratracheal Instillation of Bleomycin in Mice	69
4.5.3 Characterization of Bleomycin-Induced Lung Injury	69
4.5.4 Preparation of [¹⁷⁷ Lu]Lu-DOTA-PPB-01 and [¹⁷⁷ Lu]Lu-DOTA-PPB-03	70
4.5.5 Preparation of [¹⁴⁴ Sc]Sc-DOTA-PPB-01 and [¹⁴⁴ Sc]Sc-DOTA-PPB-03	70
4.5.6 Biodistribution Studies	70
4.5.7 <i>Ex Vivo</i> SPECT/CT Scans of the Lungs	71
4.5.8 <i>In Vivo</i> SPECT/CT Imaging Studies	71
4.5.9 <i>In Vivo</i> PET/CT Imaging Studies	71
4.5.10 Statistics	72
5 Folate Receptor-β Targeted PET/CT Imaging for the Visualization of Activated Macrophages in Interstitial Lung Disease	73
5.1 Introduction	74
5.2 Results	75
5.2.1 FR- β Expression Is Upregulated in Human ILD and Correlates with Disease Severity	75
5.2.2 FR- β Expression Is Upregulated in Experimental ILD and Changes with Disease Development	78
5.2.3 [¹⁸ F]AzaFol-PET/CT Imaging as Surrogate Marker for FR- β -Positive Macrophages Specifically Monitors Disease Development in Experimental ILD	81
5.2.4 [¹⁸ F]AzaFol PET/CT Shows Sensitivity similar to [¹⁸ F]FDG-PET/CT	81
5.3 Discussion	84
5.4 Conclusion	85
5.5 Materials and Methods	85
5.5.1 Study Design	85
5.5.2 Human Subjects	86
5.5.3 Murine Model of Bleomycin-Induced Lung Fibrosis	86
5.5.4 Histology	86
5.5.5 Immunohistochemistry on Murine Lung Tissues	87
5.5.6 Immunohistochemistry on Human Lung Tissues	88
5.5.7 Immunofluorescence	88

5.5.8	Microscopy and Image Analysis	88
5.5.9	RNA Extraction and Quantitative Reverse Transcription PCR	89
5.5.10	Hydroxyproline Assay	89
5.5.11	Radiolabeling	89
5.5.12	Biodistribution Studies	89
5.5.13	<i>In Vivo</i> and <i>Ex Vivo</i> PET/CT Imaging	90
5.5.14	Statistics	90
6	Molecular Targeted Imaging for the Stage-Specific Detection and Monitoring of Lung Remodeling in Interstitial Lung Disease	91
6.1	Introduction	92
6.2	Results	93
6.2.1	Expression of Integrin $\alpha v \beta 3$ and SSTR2 Is Increased in Different Types of ILD	93
6.2.2	Expression of Integrin $\alpha v \beta 3$ and SSTR2 Reflects Different Disease Stages of Experimental ILD	93
6.2.3	Monitoring of Integrin $\alpha v \beta 3$ with [^{177}Lu]Lu-DOTA-RGD-SPECT/CT Detects Inflammation-Dominant Lung Fibrosis	99
6.2.4	Monitoring of SSTR2 with [^{177}Lu]Lu-DOTA-NOC-SPECT/CT Detects Progressive Lung Remodeling	99
6.3	Discussion	101
6.4	Conclusion	102
6.5	Materials and Methods	103
6.5.1	Patients	103
6.5.2	Mouse Model of Bleomycin-Induced Lung Fibrosis	103
6.5.3	Histology	103
6.5.4	Immunohistochemistry on Murine Tissues	104
6.5.5	Immunohistochemistry on Human Lung Tissues	105
6.5.6	Immunofluorescence	106
6.5.7	Microscopic Image Acquisition and Analysis	106
6.5.8	Cell Culture	106
6.5.9	RNA Extraction and Quantitative Reverse Transcription PCR	106
6.5.10	Western Blotting	107
6.5.11	Radiolabeling	107
6.5.12	Biodistribution Studies	108
6.5.13	SPECT/CT Imaging	108
6.5.14	Statistics	109

7	Texture-Based Radiomics Features Discriminate Different Stages of Interstitial Lung Disease	111
7.1	Introduction	112
7.2	Results	113
7.2.1	Modeling of Different Disease Stages by Intratracheal Instillation of Bleomycin in Mice	113
7.2.2	CT-Derived Texture-Based Radiomics Features, yet not Classical Histogram-Based Radiomics Features Discriminate Different Stages of ILD	113
7.2.3	Correlation of Texture-Based Radiomics Features with Histological Changes	118
7.3	Discussion	120
7.4	Conclusion	121
7.5	Materials and Methods	122
7.5.1	Animals	122
7.5.2	Induction of Bleomycin-Induced Lung Fibrosis	122
7.5.3	Histology	122
7.5.4	Immunohistochemistry for CD45	122
7.5.5	Image Acquisition and Analysis	123
7.5.6	Pulmonary CT Scans	123
7.5.7	Radiomics Feature Calculation	123
7.5.8	Statistics	124
8	Conclusion and Outlook: Towards Precision Medicine in Interstitial Lung Disease Associated with Systemic Sclerosis	127
	Bibliography	133
	Appendix	157
	Curriculum Vitae	177